US 12,312,397 B2
Anti-O2 antibodies and uses thereof
Qun Wang, Gaithersburg, MD (US); Meghan Pennini, Gaithersburg, MD (US); Xiaodong Xiao, Gaithersburg, MD (US); Davide Corti, Bellinzona (CH); Elisabetta Cameroni, Bellinzona (CH); Martina Beltramello, Bellinzona (CH); Gilad Kaplan, Gaithersburg, MD (US); Anna DeMarco, Bellinzona (CH); and Charles K. Stover, Gaithersburg, MD (US)
Assigned to MedImmune, LLC, Gaithersburg, MD (US); and Humabs BioMed SA, Bellinzona (CH)
Filed by MedImmune, LLC, Gaithersburg, MD (US); and Humabs BioMed SA, Bellinzona (CH)
Filed on Aug. 11, 2022, as Appl. No. 17/819,199.
Application 17/819,199 is a division of application No. 16/323,185, granted, now 11,447,542, issued on Sep. 20, 2022, previously published as PCT/US2017/045480, filed on Aug. 4, 2017.
Claims priority of provisional application 62/371,402, filed on Aug. 5, 2016.
Prior Publication US 2023/0079661 A1, Mar. 16, 2023
Int. Cl. C07K 16/12 (2006.01); A61K 31/407 (2006.01); A61K 39/00 (2006.01); A61K 39/40 (2006.01); A61P 31/04 (2006.01)
CPC C07K 16/1228 (2013.01) [A61K 31/407 (2013.01); A61K 39/40 (2013.01); A61P 31/04 (2018.01); A61K 2039/505 (2013.01); A61K 2039/545 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)] 15 Claims
 
1. A method for treating or ameliorating a Klebsiella infection in a subject in need thereof comprising administering to said subject an effective amount of an antigen binding protein that specifically binds to Klebsiella pneumoniae O2 antigen and comprises a set of Complementarity-Determining Regions (CDRs): HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequences of:
SEQ. ID. NOs: 10-13, DVN or SEQ ID NO: 15, and SEQ ID NO:16, respectively;
SEQ. ID. NOs: 19-22, DVN or SEQ ID NO: 24, and SEQ ID NO: 25, respectively;
SEQ. ID. NOs: 28-31, DAS or SEQ ID NO: 33, and SEQ ID NO: 34, respectively;
SEQ. ID. NOs: 37-40, DMS or SEQ ID NO: 42, and SEQ ID NO: 43, respectively;
SEQ. ID. NOs: 46-49, DVN or SEQ ID NO: 51, and SEQ ID NO: 52, respectively;
SEQ. ID. NOs: 166-168, 175, DVN or SEQ ID NO: 177, and SEQ ID NO: 178, respectively;
SEQ. ID. NOs: 169-171, 179, DVN or SEQ ID NO: 181, and SEQ ID NO: 182, respectively;
SEQ. ID. NOs: 55-58, DMS or SEQ ID NO: 60, and SEQ ID NO: 61, respectively;
SEQ. ID. NOs: 64-67, AAS or SEQ ID NO: 69, and SEQ ID NO: 70, respectively;
SEQ. ID. NOs: 73-78, respectively;
SEQ. ID. NOs: 82-85, EVS or SEQ ID NO: 87, and SEQ ID NO: 88, respectively;
SEQ. ID. NOs: 91-94, DNN or SEQ ID NO: 96, and SEQ ID NO: 97, respectively;
SEQ. ID. NOs: 100-103, ENN or SEQ ID NO: 105, and SEQ ID NO: 106, respectively;
SEQ. ID. NOs: 109-112, ENN or SEQ ID NO: 114, and SEQ ID NO: 115, respectively;
SEQ. ID. NOs: 118-121, EVN or SEQ ID NO: 123, and SEQ ID NO: 124, respectively;
SEQ. ID. NOs: 127-130, GAS or SEQ ID NO: 132, and SEQ ID NO: 133, respectively; or
SEQ. ID. NOs: 172-174, 183, EVN or SEQ ID NO: 185, and SEQ ID NO: 186, respectively.